Infinity Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
This is the Thursday morning of the 2020 JPMorgan Healthcare Conference. Welcome, everyone. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Matt Bannon and Tessa Romero from the team. Our next presenting company is Infinity. And presenting on behalf of the company is CEO, Adelene Perkins. Adelene?
Thank you, Anupam. Thank you to JPMorgan for inviting us to present. I appreciate all of you coming this morning, and welcome to those who are participating via the webcast to learn about IPI-549, which targets immune suppressive macrophages to improve immunotherapies. And we are now in studies in over 500 patients.
I'll remind you that I'll be making forward-looking statements this morning, which you can review in more detail in our most recent 10-Q. The most important thing for you to know about Infinity and IPI-549 is that we have 5 studies that are reading out
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |